Advanced search
Publication Cover
Leukemia & Lymphoma Volume 61, 2020 - Issue 1
Submit an article Journal homepage
142
Views
7
CrossRef citations to date
0
Altmetric
Letter to the Editor

Cell-of-origin and bone marrow involvement increase specificity of defining patients with diffuse large B-cell lymphoma at high risk of CNS relapse: a study of 793 patients treated with chemoimmunotherapy in Asia

Shin Yeu OngDepartment of Haematology, Singapore General Hospital, Singapore; Correspondence[email protected]
ORCID Iconhttp://orcid.org/0000-0003-0192-6975
ORCID Icon,
Colin PhippsParkway Cancer Centre, Singapore;
,
Chandramouli NagarajanDepartment of Haematology, Singapore General Hospital, Singapore;
,
Tiffany TangNational Cancer Center, Singapore
,
Soon Thye LimNational Cancer Center, Singapore
,
Yeow Tee GohDepartment of Haematology, Singapore General Hospital, Singapore;
&
Yuh Shan LeeParkway Cancer Centre, Singapore;
show all
Pages 225-227 | Received 03 Apr 2019, Accepted 22 Jul 2019, Published online: 05 Aug 2019

References

  • Schmitz N, Zeynalova S, Nickelsen M, et al. CNS international prognostic index: a risk model for CNS relapse in patients with diffuse large B-cell lymphoma treated with R-CHOP. J Clin Oncol. 2016;34:3150–3156.
  • Klanova M, Sehn LH, Bence-Bruckler I, et al. Integration of COO into the clinical CNS International Prognostic Index could improve CNS relapse prediction in DLBCL. Blood. 2019;133:919–926.
  • Tomita N, Yokoyama M, Yamamoto W, et al. The standard international prognostic index for predicting the risk of CNS involvement in DLBCL without specific prophylaxis. Leuk Lymphoma. 2018;59:97–104.
  • Fletcher CD, Kahl BS. Central nervous system involvement in diffuse large B-cell lymphoma: an analysis of risks and prevention strategies in the post-rituximab era. Leuk Lymphoma. 2014;55:2228–2240.
  • Hosein PJ, Maragulia JC, Salzberg MP, et al. A multicentre study of primary breast diffuse large B-cell lymphoma in the rituximab era. Br J Haematol. 2014;165:358–363.
  • Kridel R, Telio D, Villa D, et al. Diffuse large B-cell lymphoma with testicular involvement: outcome and risk of CNS relapse in the rituximab era. Br J Haematol. 2017;176:210–221.
  • Villa D, Connors JM, Sehn LH, et al. Diffuse large B-cell lymphoma with involvement of the kidney: outcome and risk of central nervous system relapse. Haematologica. 2011;96:1002–1007.
  • Thakral B, Medeiros LJ, Desai P, et al. Prognostic impact of CD5 expression in diffuse large B-cell lymphoma in patients treated with rituximab-EPOCH. Eur J Haematol. 2017;98:415–421.
  • Savage KJ, Slack GW, Mottok A, et al. Impact of dual expression of MYC and BCL2 by immunohistochemistry on the risk of CNS relapse in DLBCL. Blood. 2016;127:2182–2188.
  • Camilleri-Broet S, Criniere E, Broet P, et al. A uniform activated B-cell-like immunophenotype might explain the poor prognosis of primary central nervous system lymphomas: analysis of 83 cases. Blood. 2006;107:190–196.
  • Ferreri AJ, Bruno-Ventre M, Donadoni G, et al. Risk-tailored CNS prophylaxis in a mono-institutional series of 200 patients with diffuse large B-cell lymphoma treated in the rituximab era. Br J Haematol. 2015;168:654–662.
  • Abramson JS, Hellmann M, Barnes JA, et al. Intravenous methotrexate as central nervous system (CNS) prophylaxis is associated with a low risk of CNS recurrence in high-risk patients with diffuse large B-cell lymphoma. Cancer. 2010;116:4283–4290.
  • Cheah CY, Herbert KE, O'Rourke K, et al. A multicentre retrospective comparison of central nervous system prophylaxis strategies among patients with high-risk diffuse large B-cell lymphoma. Br J Cancer. 2014;111:1072–1079.
  • Boltezar L, Prevodnik VK, Perme MP, et al. Comparison of the algorithms classifying the ABC and GCB subtypes in diffuse large B-cell lymphoma. Oncol Lett. 2018;15:6903–6912.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.